NSRX on NYSE

Nasus Pharma Ltd

Nasus Pharma Ltd is a pharmaceutical preparations company, listed on NYSE (NSRX).1

Price unavailable

Last updated Oct 20, 2026.

Overview

$1.2BRevenue, fiscal 20252
-$5.9MNet income, fiscal 20252

Compare with Indivior, Prestige Brands or Acadia Pharmaceuticals, or pick any stock.

  • TickerNSRX on NYSE1
  • IndustryPharmaceutical Preparations1
  • HeadquartersL31
  • Incorporated inIsrael3
  • Business address29 Harakevet St, Tel Aviv - Yafo, L3 66180033
  • Filer categoryNon-accelerated filer, Emerging growth company3
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

IND submission for NS002 is planned for the third quarter of 2026 following the completion of the additional Phase 2 studies.4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-0.4%Operating margin2
-0.5%Net margin2
-211.6%Return on equity2
-$4.9MFree cash flow2

Where the money goes

Where each dollar of revenue went, fiscal 2025

  • Research and development0¢$2.2M
  • Other costs100¢$1.2B

Out of $1.2B in revenue.2 The company lost money this year.

Financial statements

Operating income2-$4.9M in 2025+328% since 2023
-$6.0M-$4.0M-$2.0M02023: -$1.1M-$1.1M20232024: -$1.1M-$1.1M2024−6%2025: -$4.9M-$4.9M2025+355%
Net income2-$5.9M in 2025+457% since 2023
-$6.0M-$4.0M-$2.0M02023: -$1.1M-$1.1M20232024: -$1.5M-$1.5M2024+46%2025: -$5.9M-$5.9M2025+282%

Every line of the income statement as filed: the last 3 fiscal years, latest first.2

Period ending2025-12-312024-12-312023-12-31
Total operating expenses$4.9M$1.1M$1.1M
Operating loss from continuing operations-$4.9M-$1.1M-$1.1M
Change in fair value of convertible securities-$952.0K-$443.0K$219.0K
Other expense, net-$27.0K-$2.0K-$28.0K
Loss from continuing operations-$5.8M-$1.6M-$1.0M
Net income (loss) from discontinued operations-$51.0K$20.0K-$46.0K
Net loss-$5.9M-$1.5M-$1.1M
Basic-$0.72-$0.22-$0.15
Diluted-$0.72-$0.22-$0.20
Weighted average Ordinary Shares outstanding basic8.0M shares7.0M shares6.9M shares
Weighted average Ordinary Shares outstanding diluted8.0M shares7.0M shares7.1M shares
Research and development$2.2M$335.0K$567.0K
General and administrative$2.7M$743.0K$580.0K
Interest expense-$78.0K$29.0K$49.0K

Compare Nasus Pharma Ltd with another company

Corporate structure

Nasus Pharma Ltd sits at the top of its group. 1 entity on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Nasus Pharma Ltd

  • BALYASNY ASSET MANAGEMENT L.P. Filed SCHEDULE 13G/A on Nasus Pharma Ltd, latest Aug 14, 2026 (2 filings since May 15, 2026)
  • Funicular Funds, LP Filed SCHEDULE 13G on Nasus Pharma Ltd, latest Apr 7, 2026
  • Ronnie Hershman Filed SCHEDULE 13G on Nasus Pharma Ltd, latest Nov 13, 2025
  • Dalia Megiddo Filed SCHEDULE 13G on Nasus Pharma Ltd, latest Nov 12, 2025
  • Udi Gilboa Filed SCHEDULE 13G on Nasus Pharma Ltd, latest Nov 10, 2025
  • Capital Point Ltd. Filed SCHEDULE 13G on Nasus Pharma Ltd, latest Aug 20, 2025
  • Nasus Pharma Ltd L3

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Nasus Pharma Ltd reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, net$14.0K2 Dec 31, 2025
Operating-lease assets (leased space)$135.0K2 Dec 31, 2025

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$1.2M2 Dec 31, 2025$284.0K2 Dec 31, 2024+335.6%

Leadership

Who has led Nasus Pharma Ltd, and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Dan Benjamin Teleman2026
  2. Brendan P. O'Grady2026–now

Chief financial officer

  1. Eyal Rubin2026
  2. Oren Elmaliah2026–now
Board members and other officers (8)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorUdi Gilboa named Feb 25, 202614

Timeline

  1. Jul 31, 2026New chief executive Brendan P. O'Grady becomes CEO6
  2. Mar 27, 2026New chief executive Dan Benjamin Teleman becomes CEO5

Filings

99 filings to the SEC since October 2021: 1 annual reports, 15 insider forms, 7 large holders, 1 private raises, 75 other. The latest 20:

  1. Oct 8, 20266-K EDGAR
  2. Sep 23, 20263 EDGAR
  3. Sep 21, 20264 EDGAR
  4. Sep 18, 2026424B5 EDGAR
  5. Sep 18, 20266-K EDGAR
  6. Sep 14, 20266-K EDGAR
  7. Sep 11, 2026EFFECT EDGAR
  8. Sep 4, 20266-K EDGAR
  9. Sep 1, 2026F-3 EDGAR
  10. Aug 20, 2026EFFECT EDGAR
  11. Aug 19, 20266-K EDGAR
  12. Aug 19, 2026POS AM EDGAR
  13. Aug 17, 20266-K EDGAR
  14. Aug 14, 2026SCHEDULE 13G/A EDGAR
  15. Jul 31, 20263 EDGAR
  16. Jul 29, 20264 EDGAR
  17. Jul 28, 20266-K EDGAR
  18. Jun 22, 20264 EDGAR
  19. Jun 9, 20266-K EDGAR
  20. May 26, 2026S-8 EDGAR

The 99 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

3 open-market trades by officers, directors and large owners since October 2021: 3 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Jun 17, 2026Teleman Dan BenjaminChief Executive OfficerBuy6,550$3.10$20.3KForm 4
Apr 22, 2026Teleman Dan BenjaminChief Executive OfficerBuy2,900$3.76$10.9KForm 4
Mar 31, 2026Teleman Dan BenjaminChief Executive OfficerBuy15,000$2.04$30.6KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Feb 10, 2026Raised $15 million in a private offering of equity Form D: 15 investors so far Form D

SEC filer profile

How Nasus Pharma Ltd is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARNasus Pharma Ltd1
  • CIK0002029039
  • Employer ID (EIN)51-60227121
  • Filer statusNon-accelerated filer an emerging growth company; a shell company4
  • Incorporated inIsrael4
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address29 Harakevet St, Tel Aviv - Yafo, L3 66180031
  • Phone972 54-255-39561
  • Shares outstanding9,015,383 shares as of Dec 31, 20254
  • AuditorBrightman Almagor Zohar & Co, Tel -Aviv, Israel PCAOB ID 1197; it also attests to the company’s internal control over financial reporting4
  • On EDGAR sinceAug 30, 20241
  • Filings99 in all: 6-K (26), 3 (10), UPLOAD (10), DRS/A (7), DRSLTR (7), SCHEDULE 13G (6), 4 (5), CORRESP (5)1
    All 23 form types

    EFFECT (5), F-1 (2), F-1/A (2), FWP (2), POS AM (2), 20-F (1), 424B4 (1), 424B5 (1), 8-A12B (1), CERT (1), D (1), DRS (1), F-3 (1), S-8 (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (20-F) Mar 25, 2026

Securities registered for trading

ClassSymbolExchange
Ordinary Shares, no par valueNSRXNYSE American LLC

From the cover page of the 20-F filed Mar 25, 2026 (Section 12(b) of the Exchange Act).4

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20